
Feather forensics offers a way to root out poachers
This story was originally published by bioGraphic and appears here as part of the Climate Desk collaboration
Every year, the illegal wildlife trade ensnares millions of wild birds in a vast global industry worth up to US $23 billion. Poaching for the black market affects a huge diversity of life, including nearly half of all bird species. Songbirds and parrots are particularly popular targets, with thousands illegally caught and traded every year.
Proving that a bird sold as a pet was born in captivity, rather than poached from the wild, is difficult. Tracking a bird's origins, says Katherine Hill, an invasive species biologist at the University of Adelaide in Australia, relies on paperwork, 'which can obviously be forged relatively simply.'
Over the past few decades, however, scientists have been developing a technique that can hint at whether an animal hails from the wild or captivity. Known as stable isotope analysis, the approach involves analyzing the abundance of different forms of certain chemical elements in an animal's tissues.
Stable isotope analysis works on birds because their feathers lock in identifiable chemical signatures as they grow, creating a snapshot of a period of the bird's life, Hill says. Captive birds, for example, tend to eat corn and sorghum. Wild birds eat more fruits, nuts, and wild plant seeds. This altered diet skews the chemical analysis, giving scientists an accurate way to gauge what kinds of foods a bird has been eating.
Scientists have used stable isotope analysis to study bird diets for s everal years. But earlier projects aiming to tease out birds' origins largely focused on a few endangered parrot species with limited diets, small populations, or small ranges. Hill wanted to see if she could apply the technique to parrot species with relatively large geographic ranges that eat a wider variety of foods. In particular, she focused on four common Australian parrots that are popular as pets—galahs (Eolophus roseicapilla), sulphur-crested cockatoos (Cacatua galerita), little corellas (Cacatua sanguinea), and long-billed corellas (Cacatua tenuirostris).
Beginning in December 2020, Hill set out around Adelaide, where she scanned the streets for the vibrant white, yellow, or pink shocks of wild parrot feathers. COVID-19-related lockdowns meant it was difficult for Hill and her colleagues to visit zoos or aviaries to collect the feathers of captive parrots. Instead, they created a community-science initiative to collect feathers from the public. Spreading the word through social media, local news organizations, and other places likely to catch the eyes of animal lovers, the scientists harnessed dozens of volunteers from across South Australia who collectively sent in thousands of feathers they found in the wild or gathered from the bottom of their pets' cages. The project became a way for people to connect with nature, Hill says.
Pooling the feathers by species, and splitting them by whether they came from wild or captive birds, Hill and her colleagues found that stable isotope analysis can accurately distinguish between wild and captive galahs nearly 90 percent of the time, and the other parrot species 74 percent of the time. The isotope research from those four parrot species will provide data that other scientists can use in future studies as well.
The technique offers a potent way to identify poached birds. But it is possible, says Hill, to cheat the test. If a captive bird is fed a diet similar to what a wild one would eat—or if wild birds have particularly diverse diets or access to something similar to pet food—it could muddy the results. But, says Hill, when used with other tools, isotope analysis could tip off law enforcement that a bird might have been poached, giving the authorities reason to investigate further.
The value of stable isotope analysis is also constrained by time, Hill says. Because birds regularly grow and molt their feathers, each piece of plumage only reflects the time between molts. For many parrots, that's about a year. This means the technique would be best at identifying birds that were captured from the wild within that time frame.
Astrid Andersson, a conservation biologist at the University of Hong Kong, says the effectiveness of stable isotope analysis to distinguish between captive and wild parrots aligns with previous research, including her own work on a Chinese population of yellow-crested cockatoos.
'It's really important to expand the number of species that have this stable isotope data,' says Andersson. Different species need their own stable isotope datasets, she says. 'We need to build up the database that authorities could potentially refer to.'
Wildlife authorities don't often use stable isotope analysis in their investigations and, to date, the technique isn't being regularly used in bird-poaching investigations. But analyzing feathers could be a powerful new tool in the anti-poaching toolbox, says Kate Brandis, a wildlife forensics expert at the University of New South Wales in Australia. 'This is still a developing area,' she says. But research like Hill's is 'demonstrating that this does have a place in fighting the illegal wildlife trade.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Toronto Star
a day ago
- Toronto Star
FDA approves Moderna's new lower-dose COVID-19 vaccine
The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target.


Winnipeg Free Press
a day ago
- Winnipeg Free Press
FDA approves Moderna's new lower-dose COVID-19 vaccine
The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target. The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the U.S. has handled COVID-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said. The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.


Winnipeg Free Press
4 days ago
- Winnipeg Free Press
Trump administration cancels $766 million Moderna contract to fight pandemic flu
The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu. The company said it was notified Wednesday that the Health and Human Services Department had withdrawn funds awarded in July 2024 and in January to pay for development and purchase of its investigational vaccine. The funds were awarded through the Biomedical Advanced Research and Development Authority, or BARDA, a program that focuses on medical treatments for potential pandemics. The new vaccine, called mRNA-1018, used the same technology that allowed development and rollout of vaccines to fight Covid-19 in record time. Health Secretary Robert F. Kennedy Jr. has expressed deep skepticism regarding the safety of mRNA vaccines. The cancelation came as Moderna announced positive interim results from an early-stage trial of the vaccine that targeted H5 bird flu virus, tested in 300 healthy adults. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis,' the company said in a statement. H5N1 bird flu viruses spilled from wild bird into cattle in the U.S. last year, infecting hundreds in several states. At least 70 people in the U.S. have been sickened by bird flu infections, mostly mild. One person died. Scientists fear that continued mutation of the virus could allow it to become more virulent or more easily spread in people, with the possibility that it could trigger a pandemic. Moderna received $176 million in July 2024 and $590 million in January. The January award would have supported a late-stage clinical trial that could have determined the vaccine's efficacy against pandemic viruses, including bird flu, a company spokesman said. — The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.